U.S. Stock Market Movement: Definium surged on October 9 as JPMorgan issued its first rating and DT120 Phase III releases

Definium October 9th Surge Interpretation

Keywords: JPMorgan's First Coverage, DT120 Phase III

1. On October 9th, JPMorgan covered Definium for the first time, assigning an “Overweight” rating with a target price of $84. According to information, the company’s stock has an average rating of Buy and an average target price of $65.69.

2. On September 14th, the company announced that DT120 met the primary and all key secondary endpoints in the Panorama Phase III study for generalized anxiety disorder. The 100mcg dose demonstrated a HAM-A placebo-adjusted improvement of 5.1 points at week 12 (p<0.0001), with no new safety signals identified. The company plans to engage with regulators in Q4 2026 and submit a marketing application in the first half of 2027.

3. As of June 30th, the company held approximately $1.1 billion in cash, cash equivalents, and investments. Its main business is developing next-generation therapies for psychiatric and neurological disorders, with core candidates including DT120 and DT402, providing a financial foundation for clinical development and regulatory progress.

(Disclaimer: This content was compiled by AI technology summarizing publicly available information. For reference only and does not constitute investment advice.)